Adjusted EBITDA totalled $3.1m in Q4 2023, a recovery from the negative $5.9m in Q4 2022. Credit: MacroEcon/Shutterstock.com.

Nutex Health has reported attributable net loss of $31.6m for the fourth quarter (Q4) of 2023, as against a loss of $14.7m in Q4 2022.  

This attributable net loss in Q4 2023 includes a $29.1m non-cash impairment charges and a $1.1m goodwill impairments charge to hospital closures.  

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The company’s total revenue for the quarter ending 31 December 2023 reached $69.6m, marking a 30% increase from $53.7m recorded in the same quarter of 2022. 

Nutex Health’s Hospital division contributed significantly to this growth, with its revenue rising to $62.5m from $46.5m in the corresponding quarter of 2022. 

Revenue generated by the company’s Population Health Management division was $7m in Q4 2023 versus $7.1m in Q4 2022. 

Despite the revenue uptick, Nutex Health’s operating loss widened to $26.1m in Q4 2023 from $5.7m in Q4 last year.  

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company’s adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) in Q4 2023 totalled $3.1m, a recovery from the negative $5.9m in the previous year’s Q4.  

For the full year ended 31 December 2023, net loss attributable to Nutex Health was $45.7m, compared with a loss of $424.7m in 2022.  

Adjusted EBITDA in 2023 decreased to $10.8m from $12.5m in the previous year, while  

total revenue rose to $247.6m from $219.2m over this period. 

As of 31 December 2023, Nutex Health reported total assets of $398.2m, with cash and cash equivalents standing at $22.0m.  

Net cash from operating activities for the year amounted to $1.3m. 

Nutex Health chief financial officer Jon Bates said: “We are pleased to report 13% revenue growth, $10.8m of adjusted EBITDA and a 142% increase in hospital division operating income to $36.3m in 2023.” 

Nutex Health Chairman and CEO Tom Vo added: “Our goal for 2024 is to continue to be the leader and innovator in our industry, and to provide a very unique platform for selected growth opportunities.” 

In August 2023, Nutex Health acquired two Florida-based independent practice associations, Population Health Associates and Managed Care Insurance Consultants.